The FDA approval was based on positive data from the Augment-101 clinical trial, where Revuforj delivered robust and durable rates of remission in r/r acute leukemia patients with a kmt2a ...

Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors. The treatment, Rejuforj, will be available as soon as this month for patients with an ...